Alzheimer's Drugs and Their Application in Down Syndrome: Targeting Amyloid-Beta Accumulation

Down syndrome patients develop early-onset dementia with amyloid-beta accumulation similar to Alzheimer's disease, yet current AD treatments remain underexplored in this population. Recent monoclonal antibody therapies like lecanemab, designed to clear amyloid plaques, may warrant investigation as potential interventions for cognitive impairment in adults with Down syndrome and associated dementia.